Regorafenib for metastatic colorectal cancer after treatment for metastatic disease (terminated appraisal)

  • Technology appraisal
  • TA334
  • Published: 
Download guidance (PDF)

Advice

NICE is unable to make a recommendation about the use in the NHS of regorafenib for metastatic colorectal cancer after treatment for metastatic disease because no evidence submission was received from Bayer for the technology.